Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2–3 trial
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-09-15 17:04:17 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/s2468-1253(26)00115-9
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S2468125326001159
其他信息:
出版社: Elsevier BV
作者: Philippe Merle; Jean-Frederic Blanc; Karine Le Malicot; Jean-Marie Peron; Vincent Bourgeois; Mohamed Bouattour; Yann Touchefeu; Carole Vitellius; Faiza Khemissa Akouz; Alexandra Heurgué; Paul Girot; Eric Assenat; Eric Nguyen-Khac; Jean-Pierre Bronowicki; Juliette Viaud; Meher Ben Abdelghani; Sylvain Manfredi; Julien Edeline; Jean-Marc Phelip; Karine Le Malicot; Philippe Merle; Jean-Frédéric Blanc; Julien Edeline; Jean-Marie Peron; Vincent Bourgeois; Jean-Marc Phelip; Mohamed Bouattour; Yann Touchefeu; Carole Vitellius; Faiza Khemissa Akouz; Alexandra Heurgue; Paul Girot; Eric Assenat; Eric Nguyen Khac; Jean-Pierre Bronowicki; Juliette Viaud; Meher Ben Abdelghani; You-Heng Lam; Morgane Helyon; Marion Bolliet; Sylvain Manfredi; Simon Launay; René Gerolami; Christophe Agnello; Anaïs Jaillais; Valérie Boige; Bruno Huguenin; Pierre Guillaume Poureau; Marilyne Debette-Gratien; Benjamin Linot; Manon Allaire; Marie Lequoy; Juliette Thaury; David Tougeron; Louis-Marie Dourthe; Hélène Foisy; Pierre Nahon; Cédric Lecaille; Xavier Adhoute; Anne-Claire Frin; Nabil Baba-Hamed; Jérôme Martin-Babau; Aude Montchaud; Frédéric Di Fiore
